Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 24;22(6):e19691.
doi: 10.2196/19691.

Virtual Management of Patients With Cancer During the COVID-19 Pandemic: Web-Based Questionnaire Study

Emad Tashkandi #  1   2 , Ahmed Zeeneldin #  1   3 , Amal AlAbdulwahab #  4 , Omima Elemam #  1   5 , Shereef Elsamany #  1   3 , Wasil Jastaniah #  2   6 , Shaker Abdullah #  6 , Mohammad Alfayez #  1   2 , Abdul Rahman Jazieh #  7 , Humaid O Al-Shamsi  8   9   10
Affiliations

Virtual Management of Patients With Cancer During the COVID-19 Pandemic: Web-Based Questionnaire Study

Emad Tashkandi et al. J Med Internet Res. .

Abstract

Background: During the coronavirus disease (COVID-19) pandemic, patients with cancer in rural settings and distant geographical areas will be affected the most by curfews. Virtual management (telemedicine) has been shown to reduce health costs and improve access to care.

Objective: The aim of this survey is to understand oncologists' awareness of and views on virtual management, challenges, and preferences, as well as their priorities regarding the prescribing of anticancer treatments during the COVID-19 pandemic.

Methods: We created a self-administrated electronic survey about the virtual management of patients with cancer during the COVID-19 pandemic. We evaluated its clinical sensibility and pilot tested the instrument. We surveyed practicing oncologists in Gulf and Arab countries using snowball sampling via emails and social media networks. Reminders were sent 1 and 2 weeks later using SurveyMonkey.

Results: We received 222 responses from validated oncologists from April 2-22, 2020. An awareness of virtual clinics, virtual multidisciplinary teams, and virtual prescriptions was reported by 182 (82%), 175 (79%), and 166 (75%) respondents, respectively. Reported challenges associated with virtual management were the lack of physical exam (n=134, 60%), patients' awareness and access (n=131, 59%), the lack of physical attendance of patients (n=93, 42%), information technology (IT) support (n=82, 37%), and the safety of virtual management (n=78, 35%). Overall, 111 (50%) and 107 (48%) oncologists did not prefer the virtual prescription of chemotherapy and novel immunotherapy, respectively. However, 188 (85%), 165 (74%), and 127 (57%) oncologists preferred the virtual prescription of hormonal therapy, bone modifying agents, and targeted therapy, respectively. In total, 184 (83%), 183 (83%), and 176 (80%) oncologists preferred to continue neoadjuvant, adjuvant, and perioperative treatments, respectively. Overall, 118 (53%) respondents preferred to continue first-line palliative treatment, in contrast to 68 (30%) and 47 (21%) respondents indicating a preference to interrupt second- and third-line palliative treatment, respectively. For administration of virtual prescriptions, all respondents preferred the oral route and 118 (53%) preferred the subcutaneous route. In contrast, 193 (87%) did not prefer the intravenous route for virtual prescriptions. Overall, 102 (46%) oncologists responded that they would "definitely" prefer to manage patients with cancer virtually.

Conclusions: Oncologists have a high level of awareness of virtual management. Although their survey responses indicated that second- and third-line palliative treatments should be interrupted, they stated that neoadjuvant, adjuvant, perioperative, and first-line palliative treatments should continue. Our results confirm that oncologists' views on the priority of anticancer treatments are consistent with the evolving literature during the COVID-19 pandemic. Challenges to virtual management should be addressed to improve the care of patients with cancer.

Keywords: COVID-19; cancer; eHealth; public health; telemedicine; teleoncology.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
Respondents’ reported challenges regarding virtual management. Respondents were requested to select more than one response, if applicable. IT: information technology.
Figure 2
Figure 2
Respondents’ reported anti-cancer treatments that can be prescribed virtually.
Figure 3
Figure 3
Respondents’ reported anti-cancer treatments that can be prescribed virtually, by route. IV: intravenous. SC: subcutaneous.
Figure 4
Figure 4
Respondents’ responses regarding which anti-cancer treatments should not be interrupted.
Figure 5
Figure 5
Respondents’ responses when asked if they prefer to manage cancer patients virtually.
See this image and copyright information in PMC

Similar articles

  • Gynaecologic cancer care during COVID-19 pandemic in India: a social media survey.
    Kumari S. Kumari S. Cancer Rep (Hoboken). 2020 Oct;3(5):e1280. doi: 10.1002/cnr2.1280. Epub 2020 Sep 17. Cancer Rep (Hoboken). 2020. PMID: 32940425 Free PMC article.
  • Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
    Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Cartenì G, Cavallero D, Cavo A, Ciardiello F, Conca R, Conteduca V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, Messina C, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, Pagliuca M, Palmieri G, Parola S, Pepe S, Petrillo A, Piantedosi F, Piccin L, Picozzi F, Pietroluongo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, Zivi A, Daniele B, Ascierto PA; SCITO (Società Campana di ImmunoTerapia Oncologica). Ottaviano M, et al. J Immunother Cancer. 2020 Oct;8(2):e001154. doi: 10.1136/jitc-2020-001154. J Immunother Cancer. 2020. PMID: 33060148 Free PMC article.
  • Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.
    Ürün Y, Hussain SA, Bakouny Z, Castellano D, Kılıçkap S, Morgan G, Mckay RR, Pels K, Schmidt A, Doroshow DB, Schütz F, Albiges L, Lopes G, Catto JWF, Peters S, Choueiri TK. Ürün Y, et al. JCO Glob Oncol. 2020 Aug;6:1248-1257. doi: 10.1200/GO.20.00300. JCO Glob Oncol. 2020. PMID: 32755479 Free PMC article.
  • The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future.
    Wallis CJD, Catto JWF, Finelli A, Glaser AW, Gore JL, Loeb S, Morgan TM, Morgans AK, Mottet N, Neal R, O'Brien T, Odisho AY, Powles T, Skolarus TA, Smith AB, Szabados B, Klaassen Z, Spratt DE. Wallis CJD, et al. Eur Urol. 2020 Nov;78(5):731-742. doi: 10.1016/j.eururo.2020.08.030. Epub 2020 Sep 4. Eur Urol. 2020. PMID: 32893062 Free PMC article. Review.
  • Continuation of telemedicine in otolaryngology post-COVID-19: Applications by subspecialty.
    Samarrai R, Riccardi AC, Tessema B, Setzen M, Brown SM. Samarrai R, et al. Am J Otolaryngol. 2021 May-Jun;42(3):102928. doi: 10.1016/j.amjoto.2021.102928. Epub 2021 Jan 20. Am J Otolaryngol. 2021. PMID: 33545447 Free PMC article.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–733. doi: 10.1056/nejmoa2001017. - DOI - PMC - PubMed
    1. World Health Organization Coronavirus disease 2019. [2020-06-09]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020 Mar;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3. http://paperpile.com/b/Kg7E0Q/tEeP - DOI - PMC - PubMed
    1. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020 Mar;21(3):335–337. doi: 10.1016/S1470-2045(20)30096-6. http://europepmc.org/abstract/MED/32066541 - DOI - PMC - PubMed
    1. Shankar A, Saini D, Roy S, Mosavi Jarrahi A, Chakraborty A, Bharti SJ, Taghizadeh-Hesary F. Cancer Care Delivery Challenges Amidst Coronavirus Disease–19 (COVID-19) Outbreak: Specific Precautions for Cancer Patients and Cancer Care Providers to Prevent Spread. Asian Pac J Cancer Prev. 2020 Mar 01;21(3):569–573. doi: 10.31557/apjcp.2020.21.3.569. - DOI - PMC - PubMed